[PDF][PDF] Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States

ZM Younossi, R Tampi, M Priyadarshini, F Nader… - …, 2019 - Wiley Online Library
Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver
disease. Our aim was to estimate the total economic burden of NASH and advanced NASH …

State transitions across the Strep A disease spectrum: sco** review and evidence gaps

P Parajulee, JS Lee, K Abbas, J Cannon… - BMC Infectious …, 2024 - Springer
The spectrum of diseases caused by Streptococcus pyogenes (Strep A) ranges from
superficial to serious life-threatening invasive infections. We conducted a sco** review of …

Cost-effectiveness of a digital health intervention for acute myocardial infarction recovery

V Bhardwaj, EM Spaulding, FA Marvel, S LaFave… - Medical care, 2021 - journals.lww.com
Background: Acute myocardial infarction (AMI) is a common cause of hospital admissions,
readmissions, and mortality worldwide. Digital health interventions (DHIs) that promote self …

Estimation of transition probabilities for state-transition models: a review of NICE appraisals

T Srivastava, NR Latimer, P Tappenden - Pharmacoeconomics, 2021 - Springer
State transition models are used to inform health technology reimbursement decisions.
Within state transition models, the movement of patients between the model health states …

Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: data from Hong Kong

RP Tampi, VWS Wong, GLH Wong… - Hepatology …, 2020 - Wiley Online Library
Aim Non‐alcoholic steatohepatitis (NASH) is the progressive form of non‐alcoholic fatty liver
disease (NAFLD) and prevalence is rising in Asia due to increasing rates of urbanization …

Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

Q Zhao, R **e, W Zhong, W Liu, T Chen, X Qiu… - Cost Effectiveness and …, 2023 - Springer
Background Durvalumab plus gemcitabine and cisplatin has a significant clinical benefit for
advanced biliary tract cancer (BTC). However, the high price of durvalumab warrants an …

Annual transition probabilities of overweight and obesity in older adults: Evidence from World Health Organization Study on global AGEing and adult health

ST Lartey, L Si, P Otahal, B de Graaff… - Social science & …, 2020 - Elsevier
Overweight/obesity is becoming increasingly prevalent in sub-Saharan Africa including
Ghana. However, transition probabilities, an essential component to develop cost-effective …

Cost-utility analysis of camrelizumab plus chemotherapy versus chemotherapy alone as a first-line treatment for advanced nonsquamous non-small cell lung cancer in …

T Chen, R **e, Q Zhao, H Cai, L Yang - Frontiers in Oncology, 2022 - frontiersin.org
Purpose To evaluate the cost utility of camrelizumab plus standard chemotherapy versus
standard chemotherapy alone as a first-line treatment for advanced nonsquamous non …

Modeling the multi‐state natural history of rare diseases with heterogeneous individual patient data: A simulation study

J Broomfield, KR Abrams, S Freeman… - Statistics in …, 2024 - Wiley Online Library
Multi‐state survival models are used to represent the natural history of a disease, forming
the basis of a health technology assessment comparing a novel treatment to current …

Impact of a digitally enhanced diabetes self-management program on glycemia and medical costs

F Chen, CB Jasik, TM Dall… - The Science of Diabetes …, 2022 - journals.sagepub.com
Objective: To analyze economic savings and health impacts associated with a virtual
digitally enhanced diabetes self-management education and support (DSMES) program …